Key result
Plozasiran review summarizes clinical evidence for the APOC3-targeted siRNA to reduce triglycerides in hypertriglyceridemia.
Why the study?
Hypertriglyceridemia increases the risk of acute pancreatitis and ASCVD, motivating the evaluation of APOC3-inhibiting small interfering RNA therapies like plozasiran to reduce triglycerides.
Plozasiran is an emerging small interfering RNA therapy targeting APOC3 to reduce triglycerides in patients with hypertriglyceridemia and familial chylomicronemia syndrome.
No takes yet. Share an insight, caveat, or question.
APOC3 siRNA merits further evaluation in severe hypertriglyceridemia; leaves open its clinical role pending randomized data.
Huston et al. (2026) conducted a review in Hypertriglyceridemia and familial chylomicronemia syndrome. Plozasiran was evaluated. This review summarizes the current pharmacokinetic, pharmacodynamic, and clinical evidence for plozasiran, a small interfering RNA targeting APOC3 to reduce triglycerides in hypertriglyceridemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: